Skip to main content

Table 4 In vivo antiplasmodial efficacy of compounds 1 in C57BL/6 mice blood infected with P. berghei

From: Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model

Test group Average % parasitemia % reduction of parasitemia
Day 4 Day 6 Day 9 Day 9
Oral (20 mg/kg/day) 5.3 ± 3.9 22.7 ± 10 24.2 ± 5.6 3.7 ± 5.6
Oral (40 mg/kg/day) 5.9 ± 2 10.7 ± 5 48.6 ± 12 −93.8 ± 49.3
IV (4 mg/kg/day) 0.4 ± 0.4 1.8 ± 1.4 8.1 ± 5 61.9 ± 26
IV (8 mg/kg/day) 0 0.9 ± 0.9 5.1 ± 1.7 82.9 ± 2.5
Oral CQ (10 mg/kg/day) 0 0 2 ± 1.6 92.0 ± 0.4
Placebo 2.5 ± 2.4 7.3 ± 2.4 25.1 ± 0.4
  1. Data represent mean ± standard data points obtained from five mice